Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Roche personalized...

    Roche personalized cancer treatment Rozlytrek priced at Rs 12 lakh per month

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-17T09:15:54+05:30  |  Updated On 16 Aug 2021 3:12 PM IST

    Rozlytrek was approved by the U.S. Food and Drug Administration on Thursday to treat certain types of solid tumours, which show rare genetic anomalies called NTRK fusions.


    U.S: Roche Holding AG has priced at about $204,560 a year its personalized cancer treatment, Rozlytrek, that targets tumours with specific genetic mutations, the Swiss drugmaker said.


    The treatment will cost about $17,050 per month for adult patients, a company spokesman said on Friday. Rozlytrek will compete against German drugmaker Bayer AG's Vitrakvi, which is priced at $32,800 per month.


    Rozlytrek was approved by the U.S. Food and Drug Administration on Thursday to treat certain types of solid tumours, which show rare genetic anomalies called NTRK fusions.


    Read Also: Single dose of Xofluza flu drug as effective as Tamiflu in kids, says Roche


    The treatment also won approval to treat adults with non-small cell lung cancer, whose tumours show genetic mutations called ROS1 fusions.


    Vitrakvi, developed by Bayer in partnership with Eli Lilly and Co's Loxo Oncology, won the U.S. approved in November to treat patients with NTRK-positive solid tumours.


    Read Also: Roche wins Japan approval for personalised cancer drug Rozlytrek

    Bayercancercancer treatmentgenetic mutationlung cancerNTRK fusionspharmapharma companypharma newsRocheROS1 fusionsRozlytrekSwiss drugmakertumorsUSFDAvitrakvi
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok